Literature DB >> 19217205

Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma.

Huamao Wang1, Hua Jiang, Min Zhou, Zhibing Xu, Shiguo Liu, Bizhi Shi, Xiao Yao, Ming Yao, JianRen Gu, Zonghai Li.   

Abstract

We investigated whether EGFRvIII contributes to tumorigenicity and resistance to 5-FU in HCC cell lines. Our results show that several HCC cell lines have EGFRvIII expression. EGFRvIII-positive HCC cells grew more rapidly and had a lower sensitivity to 5-FU than EGFRvIII-negative HCC cells. For further analysis of the biological characteristics of EGFRvIII, an EGFRvIII or EGFR expression cassette was introduced into the HCC cell line, Huh-7. Compared with Huh-7 cells and Huh7-EGFR cells, Huh7-EGFRvIII not only exhibit significantly increase of cell growth in vitro and in vivo but also show enhanced migration in vitro. Furthermore, 5-FU has significantly lower inhibition effect on Huh7-EGFRvIII cells then on both Huh-7 and Huh7-EGFR cells in vitro and in vivo. Collectively, these results demonstrate that EGFRvIII plays a pivotal role in tumorigenicity and enhanced 5-FU resistance of HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19217205     DOI: 10.1016/j.canlet.2009.01.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  18 in total

1.  TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.

Authors:  Bruno-Christian Koehler; Toni Urbanik; Binje Vick; Regina-Johanna Boger; Steffen Heeger; Peter-R Galle; Marcus Schuchmann; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

2.  Numerical simulation of scaling-up an inverted frusto-conical shaking bioreactor with low shear stress for mammalian cell suspension culture.

Authors:  Ning Ding; Chao Li; Meijin Guo; Ali Mohsin; Siliang Zhang
Journal:  Cytotechnology       Date:  2019-03-08       Impact factor: 2.058

3.  A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency.

Authors:  Na Li; Yuanyuan Chu; Liangqing Yao; Xiaojun Ying; Hua Jiang; Ming Zhou; Congjian Xu
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

Review 4.  The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.

Authors:  Carmen Berasain; Matías A Avila
Journal:  J Gastroenterol       Date:  2013-12-10       Impact factor: 7.527

5.  Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III.

Authors:  Hua Jiang; Huamao Wang; Zhonghua Tan; Suwen Hu; Hai Wang; Bizhi Shi; Lin Yang; Peiyong Li; Jianren Gu; Hongyang Wang; Zonghai Li
Journal:  J Biol Chem       Date:  2010-12-16       Impact factor: 5.157

6.  Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity.

Authors:  Hai Wang; Min Zhou; Bizhi Shi; Qingli Zhang; Hua Jiang; Yinghao Sun; Jianhua Liu; Keke Zhou; Ming Yao; Jianren Gu; Shengli Yang; Ying Mao; Zonghai Li
Journal:  Neoplasia       Date:  2011-05       Impact factor: 5.715

7.  Bioprocess development for the production of mouse-human chimeric anti-epidermal growth factor receptor vIII antibody C12 by suspension culture of recombinant Chinese hamster ovary cells.

Authors:  Suwen Hu; Lei Deng; Huamao Wang; Yingping Zhuang; Ju Chu; Siliang Zhang; Zhonghai Li; Meijin Guo
Journal:  Cytotechnology       Date:  2011-02-05       Impact factor: 2.058

8.  The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.

Authors:  Yaqiong Yang; Hua Jiang; Huiping Gao; Juan Kong; Pengwei Zhang; Suwen Hu; Bizhi Shi; Pengfei Zhang; Ming Yao; Zonghai Li
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

9.  Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.

Authors:  Hideki Iwamoto; Takuji Torimura; Toru Nakamura; Osamu Hashimoto; Kinya Inoue; Junichi Kurogi; Takashi Niizeki; Reiichiro Kuwahara; Mitsuhiko Abe; Hiromori Koga; Hirohisa Yano; Robert S Kerbel; Takato Ueno; Michio Sata
Journal:  Neoplasia       Date:  2011-03       Impact factor: 5.715

10.  Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer.

Authors:  Carmen Berasain; María Ujue Latasa; Raquel Urtasun; Saioa Goñi; María Elizalde; Oihane Garcia-Irigoyen; María Azcona; Jesús Prieto; Matías A Avila
Journal:  Cancers (Basel)       Date:  2011-05-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.